News | October 27, 2025
Sanofi's Q3 profit dips marginally as Dupixent sales top €4 billion
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
The product is indicated for the chronic management of patients with Urea Cycle Disorders
Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
Updated indication expands treatment options for patients with ulcerative colitis and Crohn’s disease when tumor necrosis factor (TNF) blockers are clinically inadvisable
The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
Subscribe To Our Newsletter & Stay Updated
